The objective of this Project is to develop selective genetic and pharmacological tools to perturb the major pathways for endocannabinoid (EC) metabolism. These pathways can roughly be divided into four separate groups: 1) anandamide (AEA) biosynthesis, 2) AEA degradation, 3) 2-arachidonoyl (2-AG) biosynthesis, and 4) 2-AG degradation. Among these processes, AEA degradation is the most mature in terms of our scientific understanding and availability of research tools. Studies over the past decade using knockout mice and selective inhibitors have demonstrated that the integral membrane protein fatty acid amide hydrolase (FAAH) is the primary enzyme responsible for terminating AEA signaling in the central nervous system (CMS). In contrast, our understanding of the enzymes involved in the other major branches of EC metabolism is much less complete. Although candidate enzymes have been identified in these pathways, their actual contribution to EC metabolism in vivo remains largely unknown due to a dearth of selective research tools to probe their function in living systems. We plan to address this crucial problem by creating knockout mouse models and selective chemical inhibitors for key enzymes implicated in EC metabolism. These enzymes include: 1) the putative AEA biosynthetic enzymes, a/b-hydrolase 4 (Abh4) and glycerophosphodiesterase-1 (GDE-1), 2) the putative 2-AG degradative enzyme, monoacylgycerol lipase (MAGL), and 3) the putative 2-AG biosynthetic enzyme diacylgycerol lipase-alpha (DAGL-a). Importantly, these research efforts will be bolstered by a set of innovative technologies that will ensure efficient generation of high-quality research tools for rapid dissemination among the Program Project team and larger EC research community. Collectively, the studies described in this Project will generate the requisite genetic and pharmacological tools to systematically delineate the key enzymes involved in all major branches of EC metabolism. The following three major hypotheses will be tested: 1) AEA is biosynthesized by a pathway involving the sequential action of Abhd4 and GDE-1;2) 2-AG catabolism is regulated by multiple enzymes in vivo, with a significant contribution attributable to MAGL;3) 2-AG biosynthesis in the mature brain is predominantly controlled by DAGL-a.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Program Projects (P01)
Project #
5P01DA009789-16
Application #
8410112
Study Section
Special Emphasis Panel (ZDA1-RXL-E)
Project Start
Project End
2014-08-30
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
16
Fiscal Year
2013
Total Cost
$299,016
Indirect Cost
$23,197
Name
Virginia Commonwealth University
Department
Type
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Yun, Bogeon; Lee, HeeJung; Ghosh, Moumita et al. (2014) Serine hydrolase inhibitors block necrotic cell death by preventing calcium overload of the mitochondria and permeability transition pore formation. J Biol Chem 289:1491-504
Galdino, Giovane; Romero, Thiago; Silva, José Felippe Pinho da et al. (2014) Acute resistance exercise induces antinociception by activation of the endocannabinoid system in rats. Anesth Analg 119:702-15
Pertwee, Roger G (2014) Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications. Proc Nutr Soc 73:96-105
Vallée, Monique; Vitiello, Sergio; Bellocchio, Luigi et al. (2014) Pregnenolone can protect the brain from cannabis intoxication. Science 343:94-8
Ignatowska-Jankowska, B M; Ghosh, S; Crowe, M S et al. (2014) In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects. Br J Pharmacol 171:1392-407
Abdulnour, Joseph; Yasari, Siham; Rabasa-Lhoret, Remi et al. (2014) Circulating endocannabinoids in insulin sensitive vs. insulin resistant obese postmenopausal women. A MONET group study. Obesity (Silver Spring) 22:211-6
Grim, Travis W; Ghosh, Sudeshna; Hsu, Ku-Lung et al. (2014) Combined inhibition of FAAH and COX produces enhanced anti-allodynic effects in mouse neuropathic and inflammatory pain models. Pharmacol Biochem Behav 124:405-11
Wiley, Jenny L; Walentiny, D Matthew; Wright Jr, M Jerry et al. (2014) Endocannabinoid contribution to ?9-tetrahydrocannabinol discrimination in rodents. Eur J Pharmacol 737:97-105
Schlosburg, Joel E; Kinsey, Steven G; Ignatowska-Jankowska, Bogna et al. (2014) Prolonged monoacylglycerol lipase blockade causes equivalent cannabinoid receptor type 1 receptor-mediated adaptations in fatty acid amide hydrolase wild-type and knockout mice. J Pharmacol Exp Ther 350:196-204
Murase, Ryuichi; Kawamura, Rumi; Singer, Eric et al. (2014) Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer. Br J Pharmacol 171:4464-77

Showing the most recent 10 out of 231 publications